Follow Us

,microscope.JPG 
Indiana Association 
of Pathologists, Inc.
Histology Laboratory, Indiana Medical History Museum 
Log in

2019 IAP Fall CME* Meeting

Topics in Pathology

IU School of Medicine/IU Health

                   

Register for the meeting

Fairbanks Hall

 340 W 10th St

Indianapolis, Indiana 46202

8:30-12:00

Christopher L. Emery, BA, MD

Professor of Clinical Pathology and Laboratory Medicine

IU School of Medicine | Department of Pathology and Laboratory Medicine

Rapid Antimicrobial Susceptibility Testing (AST)


Daniel A. Rushing, MD

Professor of Clinical Medicine

IU School of Medicine | Department of Medicine 

Division of Hematology/ Oncology 

What else does the sarcoma specialist need to know from the pathologist?


Thomas M. Ulbright, MD

Lawrence M. Roth Professor Emeritus of Pathology

IU School of Medicine | Department of Pathology and Laboratory Medicine

Important Considerations and Perspectives on Testicular Germ Cell Tumors

Join us for a half-day of updates on these important topics.

*The Indiana Association of Pathologists is accredited by the Indiana State Medical Association to provide continuing education for physicians.

Click to register for the IAP 2019 Fall CME Meeting

After the IAP CME portion ends, there will be an additional CME/MOC opportunity from Medical Learning Institute/Peerview

presenting

John Longshore, PhD

Carolinas Pathology Group and Carolinas HealthCare System, USA

Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

This CME/MOC activity is jointly provided by Medical Learning Institute. Inc. and PVI, Peerview Institute for Medical Education.

This additional activity is supported by an independent educational grant by AstraZeneca.


Agenda

8:00-8:30 Registration and light breakfast

8:20-8:30 Welcome and announcements

8:30-9:30 Rapid Antimicrobial Susceptibility Testing (AST)

Christopher L. Emery, BA, MD

Professor of Clinical Pathology and Laboratory Medicine

IU School of Medicine | Department of Pathology and Laboratory Medicine


9:30-10:30 What else does the sarcoma specialist need to know from the pathologist?

Daniel A. Rushing, MD

Professor of Clinical Medicine

IU School of Medicine | Department of Medicine

Division of Hematology/ Oncology

10:30-10:45 Break

10:45-11:45 Important Considerations and Perspectives on Testicular Germ Cell Tumors

Thomas M. Ulbright, MD

Lawrence M. Roth Professor Emeritus of Pathology

IU School of Medicine | Department of Pathology and Laboratory Medicine

End of IAP Program and Lunch 11:45

12:00-1:00 Additional PeerView Program*: Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

John Longshore, PhD

Carolinas Pathology Group and Carolinas HealthCare System, USA


 

Accreditation Information (IAP Presentations)

Format

This live CME activity combines lecture with opportunity for discussion during a half-day lecture session. The session will provide CME and American Board of Pathology Continuous Certification (SAM) credits.**

CME Accreditation

The Indiana Association of Pathologists (IAP) is accredited by the Indiana State Medical Association to provide continuing education to physicians. The IAP designates this live activity for 3.0 AMA PRA Category 1TM credits. Physicians should only claim credit commensurate with their participation in the activity.

Disclosure

 In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by the IAP must demonstrate balance, independence, objectivity and scientifi c rigor. Prior to the activity, all faculty, authors, editors and planning committee members participating in an IAP sponsored activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational program.

**American Board of Pathology Continuous Certification (CC)

The Indiana Association of Pathologists if an approved provider of ABPath CC. The IAP offers CC credit for the sessions at the IAP Fall CME Meeting. The method of evaluation will be Reflective Writing. Learners will be asked to share with each other and group how they would approach the case at various stages. Learners actively participate in the conversation as judged by a group leader or observer. The outcome of the case is shared. Learners who participate in the discussion will receive CC credit. All others receive CME credit.

Building Bridges

Physicians who are not pathologists may recognize that the learning opportunity of this seminar may help close a practice gap of their own. Non-pathologist physicians are generally not eligible for membership with the IAP. However, we welcome these physicians and they may attend the meeting at the IAP member price. Email iap@indianapath.org.

NOTE: WHILE OFFERING THE CME CREDIT HOURS LISTED IN THESE PAGES, THESE ACTIVITIES ARE NOT INTENDED TO PROVIDE EXTENSIVE TRAINING IN A FIELD.

Learning Objectives

Christopher L. Emery, BA, MD

Rapid antimicrobial susceptibility testing (AST): What the future holds for the clinical laboratory

1. Name several rapid AST systems that are either FDA-approved, in development, and/or are currently in clinical trials.

2. Understand the various approaches to performing rapid AST, including growth dependent and non- growth dependent methods.

3. List several advantages and disadvantages of rapid AST systems, including instantaneous AST (iAST).

4. Understand how the implementation of rapid AST systems will impact the clinical laboratory including laboratory workflow and costs.

Daniel A. Rushing, MD

What else does the sarcoma specialist need to know from the pathologist?

Pending

Thomas M. Ulbright, MD

Important considerations and perspectives on testicular germ cell tumors

1. Know the key changes in the classification of testicular germ cell tumors in the latest iteration of the World Health Organization

2. Gain an understanding about the pathogenesis of the most common category of testicular germ cell tumors

3. Recognize the pluripotential capacity of seminoma

4. Be able to state the key differences between teratomas of prepubertal-type and postpubertal-type

5. State the diagnostic criteria for a totally regressed testicular germ cell tumor

The additional program offered after the IAP portion is accredited by a separate medical education organization and is sponsored by grant by AstraZeneca. See below.

Disclosure: In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by the IAP must demonstrate balance, independence, objectivity and scientific rigor. Prior to the activity, all faculty, authors, editors and planning committee members participating in an IAP- sponsored activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational. Disclosure is made verbally and on visual media at the presentation,



Additional PeerView Program*: Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

John Longshore, PhD

Carolinas Pathology Group and Carolinas HealthCare System, USA

Learning Objectives

Upon completion of this activity, participants will be able to:Describe molecular pathways that drive malignancy in lung cancer and oncogenic activation of tyrosine kinases, such as mutations in the EGFR, that have led to the development of specific targeted molecular treatments

Evaluate current research related to EGFR mutations in the settings of newly diagnosed NSCLC and acquired resistance in the context of the evolving treatment landscape

Assess latest clinical data on EGFR-targeted therapy in NSCLC throughout the continuum of the disease from the first-line setting to second-line setting and beyond

Discuss the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of EGFR mutation status in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance following prior EGFR TKI therapy.

Implement best practices for optimal molecular testing for evaluation of EGFR mutations and interpretation of results to guide treatment decisions throughout the disease continuum of advanced/metastatic NSCLC

*This CME/MOC activity is jointly provided by Medical Learning Institute. Inc. and PVI, Peerview Institute for Medical Education. This additional activity is supported by an independent educational grant by AstraZeneca.


Powered by Wild Apricot Membership Software